Halloween is one of the best holidays of the year. It's the perfect excuse to dive into the horror genre, whether through games, movies, or TV shows. Additionally, it is likely the only time of the ...

Universal Studios Halloween Horror Nights has unleashed two new haunted houses for its 2025 season. The first is inspired by the blockbuster film, Five Nights at Freddy’s, and the second by WWE’s ...

MSNBC will rebrand as MS NOW (My Source News Opinion World), losing its name and logo. The rebranding decision reverses a previous statement that MSNBC would keep its name. The change comes as Comcast ...

Ford claims its new midsize EV pickup will have a lower cost of ownership than a Tesla Model Y and more space than a Toyota RAV4. Starting at $30,000, it will also cost about the same as the RAV4.

AI is not invited to movie night. According to The Hollywood Reporter, Universal Pictures has started including a message in the credits of its films that indicates the movie “may not be used to train ...

July 23 (Reuters) - Comcast's (CMCSA.O), opens new tab NBCUniversal is considering launching a sports cable network that would feature content also on its Peacock platform, the Wall Street Journal ...

Study found that generic mRNA vaccine prompted anti-cancer reaction in immune system. A University of Florida research team led by UF Health oncologist Elias Sayour, center, developed an mRNA vaccine ...

The Supreme Court ruled Friday that Congress did not give up too much of its power to the Federal Communications Commission when it created a framework aimed at achieving universal service. In a 6-3 ...

The Supreme Court curtailed the power of district courts to issue “universal injunctions” in a decision Friday in the legal clash over the Trump administration’s push to end birthright citizenship.

Disney and Universal joined forces in a lawsuit against artificial intelligence image creator Midjourney, alleging copyright infringement. It is the first AI copyright lawsuit from Hollywood giants.

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led ...